Chris has nearly 20 years of experience in quantitative analysis for the pharmaceutical and biotechnology industries. At Astrazeneca, he is responsible for quantitative clinical pharmacology in late phase metabolic/renal diseases (e.g., type 2 diabetes). Prior, Chris served as AD/Group Head for clinical pharmacometrics in the Novartis Critical Care franchise and held various scientific roles at Epix Pharmaceuticals and Physiome Sciences. Chris earned his PhD in Biomedical Engineering from Duke University developing computational methods for understanding cardiac physiology in normal and diseased hearts. He also holds BS and MS degrees in Nuclear Engineering from NC State University where he developed adaptive methods for reactor simulation used for accident scenario preparedness. Chris is committed to the greater Boston clinical pharmacology, pharmacometrics and predictive modeling communities and serves as Chair for ISoP New England.